Imaging Biometrics Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Trevor Edward Brown
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Grenville Street Saint Helier Jersey JE4 8TQ
- IPO Date
- Oct 21, 2019
- Website
- iqai.ltd
- Similar Companies
- Business
- Imaging Biometrics Ltd. operates at the forefront of healthcare innovation, developing and distributing advanced medical software solutions and therapeutic agents. The company, which formally changed its name from IQ-AI Limited in May 2025, maintains its commitment to enhancing diagnostic confidence and treatment efficacy for clinicians worldwide. Its subsidiary, Imaging Biometrics LLC, based in Wisconsin, USA, specializes in creating sophisticated medical technology platforms, notably a robust portfolio in neuroimaging. These cutting-edge solutions, including offerings like IB Neuro, IB Delta Suite, IB Nimble, and IB FTB, empower medical professionals with precise analytical capabilities, facilitating a clearer understanding of diseases, particularly in neuro-oncology. Beyond its diverse imaging software, which spans applications from brain tumor analysis to kidney stone assessment and liver health, the company is also advancing a therapeutic drug candidate, oral gallium maltolate (GaM or IB003), currently undergoing clinical trials for glioblastoma treatment. Imaging Biometrics Ltd. continually broadens its reach through strategic distribution agreements, such as the expanded partnership with Blackford Analysis, and focuses on delivering comprehensive, intelligent platforms that streamline workflows and improve patient outcomes.
Imaging Biometrics sees encouraging Phase 1 trial data
Imaging Biometrics hails trial validation for brain cancer imaging tool
Imaging Biometrics says commercial momentum is 'genuine and measurable'
Imaging Biometrics unit Kirkstall wins grant to develop brain cancer 'tumour on a chip' model
Imaging Biometrics to focus on core products after review
Imaging Biometrics draws line under cancer drug plans to focus on imaging growth
Imaging Biometrics launches major upgrade to its IB Clinic platform
Imaging Biometrics technology adopted in trial aiming to reshape GBM treatment strategy
Dow up, S&P 500 level in afternoon trading but Nasdaq weighted down by Nvidia
Imaging Biometrics completes early-stage trial of new glioblastoma treatment
Imaging Biometrics buys Kirkstall in £170,000 deal with Truetide
Imaging Biometrics strikes deal to commercialise advanced brain scan software
Imaging Biometrics sees improving market conditions
Imaging Biometrics moves towards next stage as glioblastoma trial hits key milestone
Imaging Biometrics to revise FDA application for brain cancer drug after positive feedback
IQ-AI subsidiary applies to FDA for ‘breakthrough therapy'
IQ-AI's Imaging Biometrics expands distribution deal with Bayer's Blackford
IQ-AI: Advancing AI for brain tumour care and clinical trials
IQ-AI subsidiary IB installs first US system with Prism
IQ-AI files of patent and updates on trading and clinical trial